185 related articles for article (PubMed ID: 24371225)
1. Phosphorylation at Ser-181 of oncogenic KRAS is required for tumor growth.
Barceló C; Paco N; Morell M; Alvarez-Moya B; Bota-Rabassedas N; Jaumot M; Vilardell F; Capella G; Agell N
Cancer Res; 2014 Feb; 74(4):1190-9. PubMed ID: 24371225
[TBL] [Abstract][Full Text] [Related]
2. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
3. Targeted degradation of KRAS by an engineered ubiquitin ligase suppresses pancreatic cancer cell growth in vitro and in vivo.
Ma Y; Gu Y; Zhang Q; Han Y; Yu S; Lu Z; Chen J
Mol Cancer Ther; 2013 Mar; 12(3):286-94. PubMed ID: 23288781
[TBL] [Abstract][Full Text] [Related]
4. Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.
Wang GM; Wong HY; Konishi H; Blair BG; Abukhdeir AM; Gustin JP; Rosen DM; Denmeade SR; Rasheed Z; Matsui W; Garay JP; Mohseni M; Higgins MJ; Cidado J; Jelovac D; Croessmann S; Cochran RL; Karnan S; Konishi Y; Ota A; Hosokawa Y; Argani P; Lauring J; Park BH
Cancer Res; 2013 Jun; 73(11):3248-61. PubMed ID: 23580570
[TBL] [Abstract][Full Text] [Related]
5. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer.
Eser S; Reiff N; Messer M; Seidler B; Gottschalk K; Dobler M; Hieber M; Arbeiter A; Klein S; Kong B; Michalski CW; Schlitter AM; Esposito I; Kind AJ; Rad L; Schnieke AE; Baccarini M; Alessi DR; Rad R; Schmid RM; Schneider G; Saur D
Cancer Cell; 2013 Mar; 23(3):406-20. PubMed ID: 23453624
[TBL] [Abstract][Full Text] [Related]
6. STK33 kinase activity is nonessential in KRAS-dependent cancer cells.
Babij C; Zhang Y; Kurzeja RJ; Munzli A; Shehabeldin A; Fernando M; Quon K; Kassner PD; Ruefli-Brasse AA; Watson VJ; Fajardo F; Jackson A; Zondlo J; Sun Y; Ellison AR; Plewa CA; San MT; Robinson J; McCarter J; Schwandner R; Judd T; Carnahan J; Dussault I
Cancer Res; 2011 Sep; 71(17):5818-26. PubMed ID: 21742770
[TBL] [Abstract][Full Text] [Related]
7. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
8. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic KRAS induces progenitor cell expansion and malignant transformation in zebrafish exocrine pancreas.
Park SW; Davison JM; Rhee J; Hruban RH; Maitra A; Leach SD
Gastroenterology; 2008 Jun; 134(7):2080-90. PubMed ID: 18549880
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic KRAS promotes malignant brain tumors in zebrafish.
Ju B; Chen W; Orr BA; Spitsbergen JM; Jia S; Eden CJ; Henson HE; Taylor MR
Mol Cancer; 2015 Feb; 14(1):18. PubMed ID: 25644510
[TBL] [Abstract][Full Text] [Related]
12. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.
Scholl C; Fröhling S; Dunn IF; Schinzel AC; Barbie DA; Kim SY; Silver SJ; Tamayo P; Wadlow RC; Ramaswamy S; Döhner K; Bullinger L; Sandy P; Boehm JS; Root DE; Jacks T; Hahn WC; Gilliland DG
Cell; 2009 May; 137(5):821-34. PubMed ID: 19490892
[TBL] [Abstract][Full Text] [Related]
13. KRAS phosphorylation regulates cell polarization and tumorigenic properties in colorectal cancer.
Cabot D; Brun S; Paco N; Ginesta MM; Gendrau-Sanclemente N; Abuasaker B; Ruiz-Fariña T; Barceló C; Cuatrecasas M; Bosch M; Rentero C; Pons G; Estanyol JM; Capellà G; Jaumot M; Agell N
Oncogene; 2021 Sep; 40(38):5730-5740. PubMed ID: 34333552
[TBL] [Abstract][Full Text] [Related]
14. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer.
Yu S; Lu Z; Liu C; Meng Y; Ma Y; Zhao W; Liu J; Yu J; Chen J
Cancer Res; 2010 Jul; 70(14):6015-25. PubMed ID: 20610624
[TBL] [Abstract][Full Text] [Related]
15. GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB.
Bang D; Wilson W; Ryan M; Yeh JJ; Baldwin AS
Cancer Discov; 2013 Jun; 3(6):690-703. PubMed ID: 23547054
[TBL] [Abstract][Full Text] [Related]
16. Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.
Grabocka E; Pylayeva-Gupta Y; Jones MJ; Lubkov V; Yemanaberhan E; Taylor L; Jeng HH; Bar-Sagi D
Cancer Cell; 2014 Feb; 25(2):243-56. PubMed ID: 24525237
[TBL] [Abstract][Full Text] [Related]
17. Evaluating The Role Of Nitric Oxide Synthase In Oncogenic Ras-Driven Tumorigenesis.
Counter C
Redox Biol; 2015 Aug; 5():417. PubMed ID: 28162280
[TBL] [Abstract][Full Text] [Related]
18. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
19. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
20. Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.
Zhang W; Li H; Yang Y; Liao J; Yang GY
Cancer Lett; 2014 Dec; 355(2):273-80. PubMed ID: 25304374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
